Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability
Ophthalmology Glaucoma · 2024
DOI: 10.1016/j.ogla.2024.01.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Glaucoma, 2024. Verfasst von Ruolin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department Artificial Intelligence in …. Hauptthemen laut MEDLINE: Deep Learning, Visual Fields, Intraocular Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, BrightFocus Foundation, Arvo Foundation for Eye Research.
Abstract (Originalsprache)
PURPOSE: Develop and evaluate the performance of a deep learning model (DLM) that forecasts eyes with low future visual field (VF) variability, and study the impact of using this DLM on sample size requirements for neuroprotective trials. DESIGN: Retrospective cohort and simulation study. METHODS: We included 1 eye per patient with baseline reliable VFs, OCT, clinical measures (demographics, intraocular pressure, and visual acuity), and 5 subsequent reliable VFs to forecast VF variability using DLMs and perform sample size estimates. We estimated sample size for 3 groups of eyes: all eyes (AE), low variability eyes (LVE: the subset of AE with a standard deviation of mean deviation [MD] slope residuals in the bottom 25th percentile), and DLM-predicted low variability eyes (DLPE: the subset of AE predicted to be low variability by the DLM). Deep learning models using only baseline VF/OCT/clinical data as input (DLM1), or also using a second VF (DLM2) were constructed to predict low VF variability (DLPE1 and DLPE2, respectively). Data were split 60/10/30 into train/val/test. Clinical trial simulations were performed only on the test set. We estimated the sample size necessary to detect treatment effects of 20% to 50% in MD slope with 80% power. Power was defined as the percentage of simulated clinical trials where the MD slope was significantly worse from the control. Clinical trials were simulated with visits every 3 months with a total of 10 visits. RESULTS: A total of 2817 eyes were included in the analysis. Deep learning models 1 and 2 achieved an area under the receiver operating characteristic curve of 0.73 (95% confidence interval [CI]: 0.68, 0.76) and 0.82 (95% CI: 0.78, 0.85) in forecasting low VF variability. When compared with including AE, using DLPE1 and DLPE2 reduced sample size to achieve 80% power by 30% and 38% for 30% treatment effect, and 31% and 38% for 50% treatment effect. CONCLUSIONS: Deep learning models can forecast eyes with low VF variability using data from a single baseline clinical visit. This can reduce sample size requirements, and potentially reduce the burden of future glaucoma clinical trials. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander-Universität Erlangen-Nürnb…
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Department Artificial Intelligence in Biomedical Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Malone Center for Engineering in Healthcare, Johns Hopkins University School of Medicine, Baltimore, Maryland; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:…
Förderung
- NEI NIH HHS
- BrightFocus Foundation
- Arvo Foundation for Eye Research
- Research to Prevent Blindness
- National Eye Institute
- National Institutes of Health
Zitieren
APA
Wang, R., Bradley, C., Herbert, P., Hou, K., Hager, G. D., Breininger, K., Unberath, M., Ramulu, P., & Yohannan, J. (2024). Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability. Ophthalmology Glaucoma. https://doi.org/10.1016/j.ogla.2024.01.005
Vancouver
Wang R, Bradley C, Herbert P, Hou K, Hager GD, Breininger K, et al. Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability. Ophthalmology Glaucoma. 2024. doi:10.1016/j.ogla.2024.01.005
BibTeX
@article{Wang2024,
author = {Wang, Ruolin and Bradley, Chris and Herbert, Patrick and Hou, Kaihua and Hager, Gregory D and Breininger, Katharina and Unberath, Mathias and Ramulu, Pradeep and Yohannan, Jithin},
title = {Opportunities for Improving Glaucoma Clinical Trials via Deep Learning-Based Identification of Patients with Low Visual Field Variability},
journal = {Ophthalmology Glaucoma},
year = {2024},
doi = {10.1016/j.ogla.2024.01.005}
}
EUVIMED